VeinWay is an Israeli medtech startup developing new technologies to clear blood clots. The firm has so far raised $2.5 million for the treatment of venous disease.
Johns Hopkins Medicine explains that chronic venous insufficiency occurs when your leg veins don’t allow blood to flow back up to your heart. Normally, the valves in your veins make sure that blood flows toward your heart. But when these valves don’t work well, blood can also flow backwards. This can cause blood to collect (pool) in your legs. Chronic venous insufficiency is not a serious health threat. But it can be painful and disabling.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Founded in 2020 by CEO Jordan Pollack and CTO Ben Friesem, VeinWay is a pre-clinical medical device company developing a novel “one and done” catheter for recanalizing chronic venous occlusions resulting from chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, Inferior Vena Cava Filters, and indwelling dialysis catheters.
Jordan Pollack holds a bachelor’s and master’s degree in biomedical engineering from the University of Michigan, and he recently completed (Sept 2021) his MBA in Healthcare Innovation from the Interdisciplinary College in Herzaliya, Israel. Jordan worked for four years at Boston Scientific in Maple Grove, MN, USA where he rotated through three different roles every eight months including Design Assurance (DA), Operations/Manufacturing Engineering, and Process Development (PD).
VeinWay’ says that its Traversa is a first-of-its-kind device empowering physicians to cross previously uncrossable veins “quickly, safely, and reliably.” It is designed to cross any venous occlusions in thirty minutes or less.
In March, in a first-in-human, compassionate use case approved by the U.S. Food and Drug Administration, University of Michigan Health Interventional Radiologists Dr. David M. Williams and Dr. Minhaj S. Khaja successfully used VeinWay’s Traversa for venous recanalization to save a patient’s leg that was close to being amputated. Traversa enabled the physicians to recanalize a previously uncrossable vascular pathway, which included a 20 cm long blocked vein with four occluded stents.
VeinWay CEO Mr. Jordan Pollack said, “Our mission is to give surgeons the control they need to recanalize the veins of their patients safely, timely and successfully. In doing so, we hope to inspire physicians to perform more venous recanalizations for the patients that need it to relieve pain and improve mobility. The procedure at University of Michigan Health was a huge step in changing the medical landscape of venous recanalization. We would like to thank the FDA for approving the use of Traversa in this first compassionate use case as well as Drs. Williams and Khaja for their agreement to try something new. We were honored to be of service.”
